Estimating the Lost Benefits of Antiretroviral Drug Use in South Africa

被引:177
作者
Chigwedere, Pride [1 ,2 ]
Seage, George R., III [3 ,4 ]
Gruskin, Sofia [5 ,6 ]
Lee, Tun-Hou [1 ,2 ]
Essex, M. [1 ,2 ]
机构
[1] Harvard Univ, Sch Publ Hlth, AIDS Initiat, Boston, MA 02115 USA
[2] Harvard Univ, Sch Publ Hlth, Dept Immunol & Infect Dis, Boston, MA 02115 USA
[3] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA
[4] Harvard Univ, Sch Publ Hlth, Interdisciplinary Program Infect Dis Epidemiol, Boston, MA 02115 USA
[5] Harvard Univ, Sch Publ Hlth, Program Int Hlth & Human Rights, Boston, MA 02115 USA
[6] Harvard Univ, Sch Publ Hlth, Dept Populat & Int Hlth, Boston, MA 02115 USA
关键词
antiretroviral drug use; South Africa; PMTCT; lost benefits;
D O I
10.1097/QAI.0b013e31818a6cd5
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
South Africa is one of the countries most severely affected by HIV/AIDS. At the peak of the epidemic, the government, going against consensus scientific opinion, argued that HIV was not the cause of AIDS and that antiretroviral (ARV) drugs were not useful for patients and declined to accept freely donated nevirapine and grants from the Global Fund. Using modeling, we compared the number of persons who received ARVs for treatment and prevention of mother-to-child HIV transmission between 2000 and 2(1(15 with all alternative of what was reasonably feasible in the country during that period. More than 330,000 lives or approximately 2.2 million person-years were lost because a feasible and timely ARV treatment program was not implemented ill South Africa. Thirty-five thousand babies were born with HIV resulting in 1.6 million person-years lost by not implementing a mother-to-child transmission prophylaxis program using nevirapine. The total lost benefits of ARVs are at least 3.8 million person-years for the period 2000-2005.
引用
收藏
页码:410 / 415
页数:6
相关论文
共 38 条
  • [1] Potential impact of antiretroviral therapy on HIV-1 transmission and AIDS mortality in resource-limited settings
    Abbas, UL
    Anderson, RM
    Mellors, JW
    [J]. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2006, 41 (05) : 632 - 641
  • [2] *ACT SOC S AFR, 2005, ASSA 2003 SUMM STAT
  • [3] [Anonymous], 2002, REPORT GLOBAL HIVAID
  • [4] [Anonymous], ESSENTIALS EPIDEMIOL
  • [5] [Anonymous], 2006, WORLD HLTH REP
  • [6] Effectiveness and cost effectiveness of early and late prevention of HIV/AIDS progression with antiretrovirals or antibiotics in southern African adults (vol 18, pg 109, 2006)
    Bachmann, MO
    [J]. AIDS CARE-PSYCHOLOGICAL AND SOCIO-MEDICAL ASPECTS OF AIDS/HIV, 2006, 18 (04): : 415 - 416
  • [7] Cost-effectiveness of highly active antiretroviral therapy in South Africa
    Badri, M
    Maartens, G
    Mandalia, S
    Bekker, LG
    Penrod, JR
    Platt, RW
    Wood, R
    Beck, EJ
    [J]. PLOS MEDICINE, 2006, 3 (01) : 48 - 56
  • [8] South Africa's AIDS care thrown into confusion
    Baleta, A
    [J]. LANCET, 1999, 354 (9191) : 1711 - 1711
  • [9] Braitstein P, 2006, LANCET, V367, P817, DOI 10.1016/S0140-6736(06)68337-2
  • [10] The cost-effectiveness of antiretroviral treatment in Khayelitsha, South Africa - A primary data analysis
    Cleary S.M.
    McIntyre D.
    Boulle A.M.
    [J]. Cost Effectiveness and Resource Allocation, 4 (1)